利用组学技术筛选结直肠癌中KRAS G12D抑制剂耐药候选治疗靶点OA
Omics-based screening of candidate therapeutic targets for KRAS G12D inhibitor resistance in colorectal cancer
目的 筛选结直肠癌中 KRAS G12D 抑制剂耐药的潜在治疗靶点.方法 采用剂量递增法建立MRTX1133耐药的结直肠癌KRAS G12D细胞株并验证耐药表型;通过数据非依赖采集定量蛋白质组学检测敏感株与耐药株蛋白表达差异,采用Limma软件包进行差异分析(设置校正后P<0.05,|logFC|>1);基于Reactome数据库开展基因集富集分析(GSEA),结合基因本体论(GO)、京都基因与基因组百科全书(KEGG)进行功能富集,并通过STRING数据库构建蛋白-蛋白相互作用网络.结果 成功构建MRTX1133耐药细胞株;共鉴定蛋白7124 个,获得差异蛋白88个,包括NF-κB抑制剂相互作用Ras1(NKIRAS1)、纤毛相关蛋白(IQCB1)、基因编码Ⅰ型中间丝链角蛋白17(KRT17)、丝氨酸蛋白酶2(PRSS2)等.富集分析显示,缺氧、细胞骨架、氨基酸代谢等通路显著异常;缺氧相关蛋白F-actin单氧酶MICAL1可能通过激活无翅型整合位点/β-连环蛋白(WNT/β-catenin)信号通路介导耐药.结论KRAS G12D 抑制剂耐药与缺氧、细胞骨架及氨基酸代谢通路相关,NKIRAS1、IQCB1、KRT17、PRSS2、MICAL1有望成为逆转耐药的潜在靶点,其中MICAL1可能通过激活WNT/β-catenin通路发挥促耐药作用.
Objective To identify potential therapeutic targets for overcoming resistance to KRAS G12D inhibitors in colorectal cancer using quantitative proteomic strategies.Methods MRTX1133-resistant KRAS G12D-mutant colorectal cancer cell lines were established via dose escalation and verified.Quantitative proteomic analysis was conducted using data-independent acquisition(DIA).Differentially expressed proteins were identified with the Limma package under the thresholds of adj.P<0.05 and|logFC|>1.Gene set enrichment analysis(GSEA)was conducted based on the Reactome database.Functional enrichment was analyzed using GO and KEGG databases.Protein-protein interaction(PPI)networks were constructed and analyzed using the STRING database.Results MRTX1133-resistant cell lines were constructed.A total of 7124 proteins were quantified,88 of which were significantly differentially expressed,including NF-κB inhibitor-interacting Ras-like 1(NKIRAS1),IQ motif-containing protein B1(IQCB1),keratin 17(KRT17),and serine protease 2(PRSS2).Enrichment analysis found that hypoxia,cytoskeleton organization,and amino acid metabolism pathways were significantly dysregulated.In addition,the hypoxia-related F-actin monooxygenase MICAL1 might contribute to resistance to KRAS G12D inhibitors by activating the WNT/β-catenin signaling pathway.Conclusion Resistance to the KRAS G12D inhibitor MRTX1133 is closely related to the dysregulation of hypoxia,cytoskeleton,and amino acid metabolism pathways.NKIRAS1,IQCB1,KRT17,PRSS2,and MICAL1 may serve as novel candidate targets for reversing drug resis-tance.In particular,MICAL1 may promote resistance to KRAS G12D inhibitors by activating the WNT/β-catenin pathway.
洪若琳;郝杨;冯峻德;崔春萍
安徽医科大学基础医学院病理学与病理生理学教研室,合肥 230032||军事科学院军事医学研究院,北京 100850军事科学院军事医学研究院,北京 100850安徽医科大学基础医学院病理学与病理生理学教研室,合肥 230032||军事科学院军事医学研究院,北京 100850安徽医科大学基础医学院病理学与病理生理学教研室,合肥 230032||军事科学院军事医学研究院,北京 100850
医药卫生
定量蛋白质组学结直肠癌KRAS G12D抑制剂耐药
quantitative proteomicscolorectal cancerKRAS G12D inhibitordrug resistance
《军事医学》 2026 (7)
505-514,10
国家重点研发计划项目(2021YFA1300200,2022YFC3401500)
评论